Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It

After many attempts and failures to bring a disease-modifying therapy forward for Alzheimer’s disease, the triumph of Eisai Co., Ltd./Biogen, Inc.’s amyloid protofibril-clearing antibody lecanemab in the Phase III Clarity AD clinical trial energized a field that has come to expect setbacks rather than success. Researchers gathered at the recent Clinical Trials on Alzheimer's Disease (CTAD) meeting and several drug developers outlined the latest thinking on bringing forward new medicines in the area to Scrip.

Researchers, doctors and drug developers are shifting focus from finding a single drug that can slow or stop the progression of Alzheimer’s disease (AD) to multiple drugs that may be used alone or in combination